An older patient with active ulcerative colitis and coronavirus disease 2019 (COVID-19) pneumonia successfully treated with the combination of anti-TNFα therapy and azathioprine

Tsukasa Yamakawa1 · Keisuke Ishigami1 · Sae Ohwada1 · Tomoe Kazama2 · Daisuke Hirayama2 · Shinji Yoshii1 · Hiro-o Yamano1 · Hiroshi Nakase1

Received: 27 May 2022 / Accepted: 13 November 2022 / Published online: 23 November 2022 © The Author(s) 2022

Abstract
A 77-year-old patient with ulcerative colitis (UC) was transferred to our department because of worsening bloody diarrhea and abdominal pain, which was consistent with a UC flare. Two days after admission, she complained of cough and high fever. The polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was positive, and a computed tomography showed pneumonia in the left lobe, consistent with coronavirus disease 2019 (COVID-19) pneumonia. However, frequent bloody diarrhea and abdominal pain due to the UC flare persisted; therefore, an additional immunosuppressive agent needed to be considered. We initiated infliximab biosimilar (IFX-BS), and her abdominal symptoms improved. However, they deteriorated after the second IFX-BS infusion. After confirming that the patient was negative for SARS-CoV-2 by PCR, we administered a combination of azathioprine and IFX-BS. The combination treatment improved her intestinal symptoms without worsening COVID-19 pneumonia. She has remained in remission for over a year since her discharge.

Keywords Ulcerative colitis · COVID-19 · Anti-TNFα antibody

Introduction
Since December 2019, the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic [1, 2]. COVID-19 has various clinical presentations, with some patients being asymptomatic or having mild symptoms. However, the disease can become severe and result in hospitalization, respiratory failure, or death, with fatality rates ranging from 2.3 to 7.2% [3–5].

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis (UC), is a general term for chronic or relapsing inflammatory diseases of the gastrointestinal tract [6]. Many IBD patients require treatment with immunosuppressive drugs, which can increase the risk of...
infection [7]. There is great concern for patients with IBD to develop severe pneumonia owing to immunosuppressive states [5]. However, there are few reports on the initiation of immunosuppressive drugs in patients with IBD in the midst of COVID-19 infection. Herein, we present an older patient with active UC and COVID-19 pneumonia who was successfully treated with an anti-tumor necrosis factor (TNFα) agent and azathioprine (AZA) while appropriately monitoring the COVID-19 infection.

**Case report**

A 77-year-old woman was diagnosed with UC 6 months previously. After she was started on oral 5-aminosalicylic acid (5-ASA), her abdominal symptoms improved. However, her UC flared, and she was transferred to our department for further treatment. Blood tests showed a hemoglobin level of 10.9 g/dL, a C-reactive protein level of 1.89 mg/dL, and an erythrocyte sedimentation rate of 44 mm/h (Table 1). Despite the increased serum level of PR3-anti-neutrophil cytoplasmic antibody (ANCA) in this case, the patient showed no renal dysfunction, abnormal urinalysis, cutaneous symptoms, and neurologic symptoms related to ANCA-associated vasculitis. Stool culture and tests for pathogens, including *Clostridioides difficile*, were all negative. Although the inflammation was limited to the rectum at onset, it extended into the entire colon with a Mayo endoscopic subscore of 2 (Fig. 1a, b). Histological examination of biopsies in each part of the colon confirmed the destruction of the glandular epithelium with crypt abscess and severe inflammatory cell infiltration. These clinical and endoscopic findings were consistent with those of moderate UC.

Two days after admission, the patient complained of a cough and fever of 38.5 °C with a decline in peripheral capillary oxygen saturation (SpO2) to 93%. Chest radiography showed a slight reticular pattern, and computed tomography showed a ground-glass appearance with consolidation in the subpleural areas of the left lobe (Fig. 2). The polymerase chain reaction (PCR) test for SARS-CoV-2 was positive, and we diagnosed her with COVID-19 pneumonia. The patient did not undergo vaccination against SARS-CoV-2 prior to the COVID-19 infection. According to the WHO COVID-19 disease severity categorization, the patient was classified as a moderate case. Although the patient had COVID-19 pneumonia, frequent bloody diarrhea and abdominal pain due to the UC flare persisted; therefore, additional immunosuppressive agents needed to be considered. We initiated infliximab biosimilar (IFX-BS) (5 mg/kg), which improved the clinical activity of UC from a partial Mayo score of 9 to 2. However, her intestinal symptoms gradually deteriorated after the administration of the second dose of IFX-BS. We confirmed that the patient was negative for SARS-CoV-2 by PCR and started 50 mg/day of AZA before the next IFX-BS infusion. After receiving a combination of IFX-BS and AZA, her intestinal symptoms improved (Fig. 3). Regarding her COVID-19, she temporarily required oxygen administration; however, her respiratory symptoms improved without additional therapeutic agents for COVID-19 pneumonia. Follow-up endoscopy performed 1 year and 3 months after the first IFX-BS administration showed mucosal healing.

**Table 1** Laboratory data on admission

| CBC            | Biochemistry       | Serological test  |
|----------------|--------------------|-------------------|
| WBC 6,800/μl   | TP 6.5 g/dL        | IgG 2336 mg/dL    |
| Neut 64.0%     | Alb 2.2 g/dL       | IgM 53 mg/dL      |
| Lym 20.0%      | T-bil 0.4 U/L      | IgA 412 mg/dL     |
| RBC 3.42 × 10⁹/μl | AST 20 U/L     | PR3-ANCA 86.1 U/ml|
| Hb 10.9 g/dl   | ALT 16 U/L         | MPO-ANCA (−)      |
| Hct 32.8%      | LDH(IFCC) 232 U/L  |                   |
| Plt 39.3 × 10⁶/μl | ALP(JSCC) 136 U/L |                   |
| Infectious marker | γ-GTP 22 U/L    | Coagulation       |
| HBs-Ag (−)     | AMY 34 U/L         |                   |
| HCV-Ab (−)     | ChE 88 U/L         | PT 11.6 s         |
| RPR (−)        | BUN 6 mg/dL        | PT(%) 101.3%      |
| TPLA (−)       | Cr 0.57 mg/dL      | APTT 31.3 s       |
| CMV-IgM (−)    | FBS 86 mg/dL       | Fibrinogen 464 mg/dL|
| CMV-IgG (+)    | HbA1c(NGSP) 6.5%   | D-dimer 2.6 μg/mL |
| CMV-Antigenemia (−) | CRP 1.89 mg/dL |                   |
| Tb (ELISpot) (−) | Ferritin 423.0 ng/mL | ESR 44 mm/hr    |
| SARS-CoV-2 PCR (−) | SAA 323.8 μg/mL  |                   |
with scarring (Fig. 1c, d), and she has been in remission for over a year.

**Discussion**

Here, we present a case of an older patient with moderately active UC and COVID-19 pneumonia, who was successfully treated with an anti-TNFα agent and AZA, while appropriately monitoring the COVID-19 infection.

COVID-19, caused by SARS-CoV-2, is an infectious disease that affects the respiratory system. There is convincing evidence that the rates of both morbidity and mortality related to COVID-19 are higher in older patients with comorbidities [7]. A multicenter registry cohort study, Japan COVID-19 surveillance in IBD (J-COSMOS), also revealed that older age, higher body mass index, and steroid use were independent risk factors for COVID-19 severity [8]. The mortality rate was 8.3% in IBD patients over 70 years of age and 20.2% in those over 80 years of age [3, 5].

Patients with IBD are treated with 5-ASA, corticosteroids, thiopurines, and molecular-targeting agents, depending on the extent and severity of the disease [9]. Therefore, both physicians and patients with IBD are concerned about developing COVID-19 in IBD patients while on immunomodulatory therapy. Based on the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) and J-COSMOS data, older age and the use of steroids contributed to the severity of COVID-19, while anti-TNFα agents did not [3, 5, 8]. Moreover, anti-TNFα agents have been reported to control the multisystem inflammatory syndrome related to COVID-19 [10]. Therefore, we first selected anti-TNFα therapy for this patient. Although patients with COVID-19 primarily experience respiratory symptoms, several reports have indicated how the severity of COVID-19

![Fig. 1 Colonoscopy revealing continuous loss of vascular marking, erosions, and bleeding in the entire colon. a the cecum and b the rectum Mucosal healing with scarring was confirmed after combination treatment with an anti-TNFα agent and azathioprine c the cecum and d the rectum](image-url)
and gastrointestinal symptoms are associated [11, 12]. The angiotensin-converting enzyme 2 receptor to which SARS-CoV-2 binds is highly expressed in the small and large intestines, suggesting that SARS-CoV-2 may directly affect the intestinal epithelium and cause gastrointestinal symptoms [13, 14]. Furthermore, SARS-CoV-2 infection induces several proinflammatory cytokines such as TNFα, interleukin (IL) -1, and IL-6, and activates the NLR family pyrin domain containing 3 (NLRP3) inflammasome pathway which is important for the host’s defense during viral infection [15– 17]. These data suggest that SARS-CoV-2 infection may have contributed to the UC flares in the present case.

Another important point to note in this case is that the administration of an anti-TNFα agent did not worsen her COVID-19 pneumonia. Regarding the relationship between TNFα and COVID-19, TNFα is involved in acute inflammatory reactions and acts as an inflammation amplifier [18]. It also mediates lung inflammation and acute respiratory distress syndrome by reducing CD4+ and CD8+ T-cell levels, which are essential to the host’s defense against respiratory viruses in patients with severe COVID-19 [19–21]. Hussel et al. reported that TNFα depletion reduced the pulmonary recruitment of inflammatory cells, cytokine production by T cells, and the severity of illness without preventing virus clearance [22].
Several studies on antibody titers against the SARS-CoV-2 vaccine for patients with IBD have demonstrated that antibody titers were lower in patients treated with anti-TNFα antibody than in those without it [23, 24]. On the other hand, it has been reported that the T-cell immune response, even in patients with IBD receiving immunomodulators and biologics, was not different from that of healthy individuals [23, 24]. Taken together, these data strongly support the clinical course that anti-TNFα agents do not worsen the COVID-19 infection. Alhalabi et al. reported a case of a UC patient with COVID-19 pneumonia who was safely treated with an anti-TNFα agent [25]. However, data remain limited on the efficacy and the safety of anti-TNFα treatment in patients with COVID-19, based on large-scale clinical trials.

There is no clear consensus as to whether IBD patients with COVID-19 should continue IBD treatment. A sub-analysis of J-COSMOS data showed that neither continuation nor discontinuation of IBD medications affected COVID-19 severity, and that discontinuation of medications did not contribute to UC flares during COVID-19 [26]. However, considering its potential contributions of controlling intestinal inflammation in IBD patients to prevent SARS-CoV-2 infection and controlling COVID-19 exacerbations, aggressive therapeutic intervention is warranted in patients with highly active IBD, and patients with refractory IBD should continue the current treatment even if they develop COVID-19.

In this case, we first treated the patient with IFX-BS alone and finally required a combination therapy of IFX-BS and AZA to induce remission. SECURE-IBD and J-COSMOS data showed that IBD patients receiving corticosteroids and a combination of anti-TNFα antibody and immunosuppressive drugs at the time of diagnosing COVID-19 pneumonia had a higher severity rate of COVID-19 compared to patients receiving anti-TNFα antibody monotherapy [5, 8]. Previous reports have also shown that AZA attenuates the immune response to the virus [27, 28]. Therefore, we initially used IFX-BS alone. However, her symptoms deteriorated after the second infusion of IFX-BS because of the therapeutic impact of the antibody production against IFX-BS, owing to this its characteristics as chimeric antibody [29]. We added AZA to prevent loss of response after confirming the negativity of SARS-CoV-2 by PCR. Consequently, her intestinal symptoms improved without worsening the COVID-19 pneumonia.

In summary, we encountered a case of an older patient with moderately active UC and COVID-19 pneumonia who was successfully treated with an anti-TNFα agent and AZA. The current case suggests the importance of immunomodulatory therapy in patients with active UC while appropriately monitoring the COVID-19 infection. However, we need to accumulate cases similar to our case to evaluate the effectiveness and safety of the combination therapy of anti-TNFα agents and immunosuppressive drugs for patients with IBD who have COVID-19.

Acknowledgements We would like to thank Editage (www.editage.com) for English language editing.

Data availability The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations

Conflict of interest None of the authors have any conflicts of interest to declare for this article.

Human rights All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent Written informed consent was obtained from the patient. Data availability statement: The data underlying this article will be shared on reasonable request to the corresponding author.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Morens DM, Daszak P, Taubenberger JK. Escaping pandora’s box — another novel Coronavirus. N Engl J Med. 2020;382:1293–5.
2. Du M, Cai G, Chen F, et al. Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID-19. Gastroenterol. 2020;158:2298–301.
3. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–6.
4. Wu Z, McGoogan JM. Characteristics of and Important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323:1239–42.
5. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not tnf antagonists, are associated with adverse COVID-19 Outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481–491.e3.
6. Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489–526.
7. Dolinger MT, Person H, Smith R, et al. Pediatric crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr. 2020;71:153–5.
8. Monteleone G, Ardizzzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis. 2020;14:1334–6.
9. Nakase H, Hayashi Y, Hirayama D, et al. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol. 2022;57:174–84.
10. Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21: 103017.
11. Cheung KS, Hung IFN, Chan PPy, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis. Gastroenterology. 2020;159:41–95.
12. Hayashi Y, Wagatsuma K, Nojima M, et al. The characteristics of gastrointestinal symptoms in patients with severe COVID-19: a systematic review and meta-analysis. J Gastroenterol. 2021;56:409–20.
13. Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831–3.
14. Burgueño JF, Reich A, Hazime H, et al. Expression of SARS-CoV-2 entry molecules ace2 and tmprss2 in the gut of patients with IBD. Inflamm Bowel Dis. 2020;26:797–808.
15. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging Coronavirus. Nat Rev Microbiol. 2016;14:523–34.
16. Dvornikova KA, Bystrova EY, Churilov LP, et al. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep. 2021;48:5745–58.
17. Xu H, Akinyemi IA, Chitre SA, et al. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway. Virology. 2022;568:13–22.
18. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407–9.
19. Kkokotis G, Kitsou K, Xynogalas I, et al. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther. 2021;55:154–67.
20. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol. 2012;12:136–48.
21. Schmidt ME, Varga SM. The CD8 T Cell response to respiratory virus infections. Front Immunol. 2018;9(9):678.
22. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol. 2001;31:2566–73.
23. Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair sars-cov-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients. J Crohns Colitis. 2022;16:389–97.
24. Reuken PA, Andreas N, Grunert PC, et al. T Cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease. J Crohns Colitis. 2022;16:251–8.
25. Alhalabi M, Eddin KA, Ali F, et al. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis. Medicine. 2022;101: e28722.
26. Hayashi Y, Nakase H, Hisamatsu T. J-COSMOS group Should we continue or discontinue inflammatory bowel disease medication in patients with coronavirus disease 2019? Gastroenterology. 2022;163:338–9.
27. Kirchgesner J, Lemaître M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337-346.e10.
28. Rahier JF, Magro F, Abreu C. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in Inflammatory bowel disease. J Crohns Colitis. 2014;8:443-46.
29. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.